title: New therapeutic options of carcinoid syndrome metastatic to the liver.
abstract: Carcinoid syndrome is a relatively rare disease, generally associated with poor prognosis. Conventional diagnostic and therapeutic methods often prove inadequate and ineffective. New therapeutic options have recently been provided by Radiolabeled long-acting somatostatin analogs (Octreotide), alpha interferon, 131 MIBG and non-pharmacological methods--embolization of the hepatic artery, gene therapy, and combined therapies.
authors.affiliation: Department and Clinic of Internal Medicine and Nephrology, Department of Family Medicine, Medical University, Warsaw, Poland.
authors.forename: K A
authors.initials: KA
authors.lastname: Wardyn
authors.forename: K
authors.initials: K
authors.lastname: Zycińska
authors.forename: M
authors.initials: M
authors.lastname: Oledzka-Oreziak
authors.forename: K
authors.initials: K
authors.lastname: Ostrowski
authors.forename: M
authors.initials: M
authors.lastname: Krawczyk
authors.forename: L
authors.initials: L
authors.lastname: Królicki
authors.forename: M
authors.initials: M
authors.lastname: Caplin
mesh_terms: D019797:3-Iodobenzylguanidine / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology; D002276:Carcinoid Tumor / Q000473:pathology* / Q000601:surgery / Q000628:therapy*; D006801:Humans; D016898:Interferon-alpha / Q000494:pharmacology; D008099:Liver / Q000473:pathology*; D008113:Liver Neoplasms / Q000556:secondary*; D009362:Neoplasm Metastasis; D013004:Somatostatin / Q000494:pharmacology
chemical_list: D000970:Antineoplastic Agents; D016898:Interferon-alpha; D019797:3-Iodobenzylguanidine; D013004:Somatostatin